Osborne Clarke advises MedAnnex on £11.5M Morningside ventures investment

Written on 1 August 2019

International legal practice Osborne Clarke has advised MedAnnex, on its £11.5 million equity investment led by Morningside Ventures, a major investor in the global life sciences sector.

MedAnnex is an award-winning Scottish biotechnology company developing innovative approaches to treating autoimmune diseases and other medical conditions.

The funds will be used in conjunction with recent grant awards from Innovate UK and Scottish Enterprise to accelerate MedAnnex’s research and development activities. In collaboration with experts at a number of academic institutions including UCL, Glasgow University and Anglia Ruskin University, MedAnnex is developing therapeutic antibodies with the potential to treat a range of diseases.

Partner and head of Osborne Clarke’s UK life science and healthcare group, Dr Janita Good, and Senior Associate Jonathan Falconer advised MedAnnex.

Osborne Clarke’s life science and healthcare sector team has a strong track record of providing highly sophisticated advice to biotech clients on cutting-edge issues, across multiple service lines. They work with the biggest pharma and medical devices companies in the market.

Connect with one of our experts

Jonathan Falconer

Senior Associate, (New Zealand Qualified), UK

T +44 20 7105 7834

Email Jonathan

Full Biog